English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04624204 /

MK-7339-013

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Pembrolizumab (MK-3475) In Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib (MK-7339), Compared To Concurrent Chemoradiation Therapy Alone In Participants With Actively Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: